 Over the past couple of years, my Aquestive Therapeutics AQST thesis has been fixated on valuation and their two most important value drivers, Libervant and AQST-109. AQST-109 is the first and only oral epinephrine candidate to establish grades comparable to epinephrine auto-injectors. Aquestive expects to start the pivotal study before year-end. 